Watching Early: See Why (GOAI) is Already Up Our Morning Radar

Any content you receive is for information purposes only. Always conduct your own research.  *Sponsored Jeff Ackerman Has EVA Live, Inc. (Nasdaq: GOAI) On Watch This Morning—Tuesday, April 28, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Full Coverage On (GOAI) Starts Now Pull Up (GOAI) While It’s Still Early… April 28, 2026 Watching Early | See Why (GOAI) is Already Up Our Morning Radar Dear Reader, The digital advertising landscape is undergoing a seismic shift as legacy systems struggle to keep pace with the speed of modern data. EVA Live, Inc. (Nasdaq: GOAI) is positioning itself at the center of this transformation by deploying a proprietary AI architecture built to reduce the waste currently weighing on global marketing budgets. If (GOAI) sounds familiar, it should — last month, we brought it to your attention as it made an approximate 32% session-to-session move. And that’s just one of the reasons why (GOAI) is topping our watchlist this morning—Tuesday, April 28, 2026. But keep in mind, (GOAI) has less than 8M shares listed as available to the public. When companies have small public floats like this, the potential exists for significant swings if demand begins to change. (GOAI) recently made an approximate 140% move in less than 2 months, from around $2.75 on February 6 to $6.67 on March 19, according to Barchart. With a potential $1.9T market in focus, this Los Angeles-based firm is showing why intelligent automation is becoming a requirement for enterprise performance. By engineering a foundation that competitors are only now beginning to chase, the company is redefining what it means to be an “intelligent” ad server. See (GOAI)’s latest corporate presentation here. Redefining the Ad-Server Architecture EVA Live, Inc. (Nasdaq: GOAI) operates as a high-growth, AI-driven digital advertising and marketing technology company that is fundamentally re-engineering how brands communicate with consumers. Unlike traditional platforms that rely on manual tuning and delayed data, (GOAI) has developed a next-generation AI ecosystem designed for high margins, recurring expansion, and sustained long-term growth. By building their technology from the ground up with proprietary real-time learning technology, they have created a foundation that allows for continuous improvement without manual human intervention. The company's product lineup is spearheaded by NeuroServer, an AI ad engine capable of powering more than 10,000 simultaneous campaigns with advanced automation and precision. This server represents a critical shift away from traditional A/B testing, which the company identifies as inefficient and slow. Instead, NeuroServer utilizes continuous real-time learning to optimize ad generation and deployment across multi-platform and social distributions. This allows the system to adapt to market changes instantly, providing a level of agility that human-managed campaigns simply cannot match. This core technology is complemented by Fraud Fence, a dedicated protection layer. In an era where manual optimization often lags behind real performance, Fraud Fence is designed to detect and block suspicious activity, protecting more than a quarter of a client's ad budget from being lost to fraudulent traffic. To finalize the marketing funnel, IntelliChat provides an always-on AI conversion platform. This tool chats, texts, and calls to qualify leads and support customers around the clock, ensuring that no traffic is wasted and conversion rates are maximized. Strategic Execution and Market Potential The digital marketing industry is a massive frontier, with revenue forecasts suggesting a climb toward $1.9T by 2035. Despite this scale, the market remains plagued by fragmented campaign management and manual optimization cycles that fail to catch waste in real-time. EVA Live, Inc. (Nasdaq: GOAI) is addressing these challenges by replacing manual labor with scalable AI automation. The company’s internal data suggests that this automation can boost client ROI by up to 40%, which naturally drives larger budgets onto the platform. The business model behind GOAI is built for scalability and predictability. It generates revenue through recurring revenue streams such as subscription and platform fees that generate predictable monthly income. These are augmented by performance-based fees tied directly to the ROI improvements delivered by the NeuroServer, aligning the company’s success directly with that of its clients. This "sticky" product ecosystem is designed for high client retention across multiple industries, ensuring long-term customer value. Recent operational milestones underscore the speed of this expansion. In March 2026, (GOAI) reported that its revenues surged 82.6% to $17M, while the company successfully swung to a net income of $8.1M. This financial pivot was driven by accelerating AI adoption and consistent 20% quarter-over-quarter growth across core operations. Furthermore, the company recently secured strategic growth financing to accelerate its platform expansion as part of its 2026 growth strategy. Competitive Positioning and Future Roadmap While many firms are just now integrating basic AI tools, EVA Live has spent the past decade engineering the next generation of ad-server technology. This head start has allowed them to move beyond development and into significant market validation. The company recently announced a successful B2B beta launch that validated enterprise demand, alongside the launch of an interactive B2B web application to support rapid client acquisition. Innovation continues to be the primary growth driver for the company. In early 2026, the company launched Fast Quote Direct™, a disruptive AI quoting engine specifically targeting the online lead generation industry. This followed the official debut of the NeuroServe platform, further expanding the company's footprint in high-fidelity digital media advertising. These tools are designed not just to compete, but to disrupt traditional lead generation and ad serving models entirely. Leadership is also leaning into the evolution of financial markets. In March 2026, EVA Live, Inc. (Nasdaq: GOAI) announced it was aligning with Nasdaq’s tokenization push. The company engaged Anderson Kill P.C. to execute a tokenization strategy for (GOAI), signaling a commitment to modernizing not just its technology, but its corporate financial structure. This move reflects the broader vision of Founder and CEO David Boulette, who has signaled strong confidence in the company's disciplined growth trajectory. The management team supporting this vision brings a track record of delivering advanced AI products and optimizing large-scale systems. Alongside CEO David Boulette, the team includes CFO Imran Firoz and Chief Intelligence Officer EVA. The board of directors provides additional strategic oversight, with leadership experience drawn from enterprise software and high-growth technology companies. With $25M in gross revenue highlighted for 2025 and a clear path toward a $1.5T industry potential, (GOAI) is operating at the forefront of the AI advertising revolution. 7 Reasons Why (GOAI) is Topping Our Watchlist This Morning—Tuesday, April 28, 2026… 1. Small Float: with less than 8M shares listed as available to the public, (GOAI)’s small float could witness the potential for big moves if demand begins to shift. 2. Recent Momentum: after an approximate 32% session-to-session move last month, (GOAI) is back at the top of the watchlist for Tuesday, April 28, 2026. 3. Focus on the Chart : from around $2.75 on February 6 to $6.67 on March 19, (GOAI) made an approximate 140% move in less than two months. 4. AI Platform: built around proprietary real-time learning technology, (GOAI) is targeting inefficiencies in digital advertising automation. 5. NeuroServer Scale: with an AI ad engine designed to power more than 10,000 simultaneous campaigns, (GOAI) is focused on high-volume automation. 6. Revenue Surge: after reporting revenue up 82.6% to $17M and net income of $8.1M in March 2026, (GOAI) has recent financial traction to review. 7. Tokenization Strategy: by engaging Anderson Kill P.C. for a tokenization strategy, (GOAI) is also aligning itself with Nasdaq’s tokenization push. Pull Up (GOAI) While It’s Still Early… The intersection of AI and digital media is creating a winner-take-all environment where technical superiority is the only currency that matters. EVA Live, Inc. (Nasdaq: GOAI) has spent a decade engineering the foundation for this moment, and their recent shift into pro-fit-ability suggests the "efficiency advantage" is translating into real-world results. As they move forward with their 2026 expansion and tokenization plans, (GOAI) remains a central figure for those monitoring the evolution of the $1.5T digital marketing sector. We have all eyes on (GOAI) this morning. Pull up (GOAI) while it’s still early. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 04/27/2026 and ending on 04/28/2026 to publicly disseminate information about (GOAI:US) via digital communications. Under this agreement, Awareness Consulting Network LLC has paid TD Media LLC one hundred twenty six thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid two hundred sixteen thousand USD (“Funds”). These Funds were part of the one hundred twenty six thousand USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (GOAI:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/goai-CNlnZ/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe Update Profile | About our service provider Sent by jeff@stocknewstrends.com

Pull This Up Early: (SRFM) is Already at the Top of Today’s Watchlist—Here’s Why

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored See Why (SRFM) Just Landed on Our Watchlist This Morning —Tuesday, April 28, 2026 Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Consider Starting Your Own Research On (SRFM)... [ Company Website ] | [ SRFM’s Corporate Portal ] April 28, 2026 Pull This Up Early | (SRFM) is Already at the Top of Today’s Watchlist—Here’s Why Dear Reader, Air mobility just had one of its most interesting days of the year, and one NYSE-listed company is squarely in the middle of it. Earlier this week, the Chairman, CEO, and Co-Founder of Surf Air Mobility (NYSE: SRFM) issued a joint letter directly to shareholders, raised 2026 Adjusted EBITDA guidance, and put their own capital back into the company. In that letter, (SRFM) improved its 2026 Adjusted EBITDA loss guidance by approximately 40%, from the prior range of $50-$40Mto a new range of $30-$25M. Revenue guidance was reaffirmed at $128-$138M for 2026, reflecting 20-30% growth over 2025. On the same day, the company announced $30M in new capital structured to minimize dilution: $15M in non-dilutive aircraft-backed credit and $15M in common equity led by the co-founders with officers, directors, and existing institutional partners adding shares alongside them. Management said it plainly in the letter: "We are obtaining liquidity in the least dilutive manner and chose this path because we believe in the plan and are investing our own money behind it." Zoom out, and the opportunity is sitting in one of the largest untapped verticals in aviation. The regional air mobility market is projected to expand to $75-$115B globally by 2035, and the global eVTOL aircraft market is forecast to grow from around $5B in 2026 to roughly $216B by 2035, an increase of more than 4,000%. These are just some of the reasons why Surf Air Mobility (NYSE: SRFM) just landed back on our radar... and why it’s topping my watchlist - this Tuesday, April 28, 2026. Keep reading to learn more about Surf Air Mobility (NYSE: SRFM). The BETA ALIA in Surf Air livery. SRFM has placed a firm order for 25 aircraft with options for up to 75 more. Surf Air Mobility Inc. (SRFM) Surf Air Mobility (NYSE: SRFM) is a Los Angeles-based air mobility platform and one of the largest commuter airlines in the United States by scheduled departures. In 2025, the company flew more than 300,000 passengers on over 60,000 scheduled departures, generating $107M in revenue, and posted three consecutive quarters of positive Adjusted EBITDA in airline operations. Beyond flight operations, (SRFM) is building the digital backbone of air mobility, an AI-enabled operating system designed to transform how key stakeholders in the industry manage everything from scheduling to compliance to booking. And this next-gen platform, powered by Palantir Technologies' (NASDAQ: PLTR) Foundry and AIP platforms, is not just for internal use. Surf Air Mobility is commercializing its AI-enabled SurfOS software across the broader air mobility industry, with BrokerOS already commercially live since December 2025 and 29 brokers enrolled on the platform as of this week's letter. Latest News: SurfOS Expands With New Fuel and Crew Reserve Modules On April 27, (SRFM) announced the release of two new SurfOS modules now live within its scheduled airline operations: fuel optimization and crew reserve optimization. The fuel module helps reconcile fuel uplift records against vendor invoices, track actual versus planned burn by flight, route, aircraft, and crew, and surface anomalies in both consumption and billing. The crew reserve module automates reserve crew assignments by base, tracks coverage gaps, and flags chronic over- or under-coverage. Together, these modules push SurfOS deeper into day-to-day airline operations, with a focus on cost control, staffing efficiency, and better operating visibility. SurfOS Is Producing Measurable Results Yesterday's shareholder letter went beyond guidance and capital structure. It laid out concrete operational numbers that show SurfOS is no longer a pitch deck. It is already helping produce measurable results inside the business. Airline Operations (Southern Airways and Mokulele): • Controllable completion rate hit 98% in Q4 2025 • On-time departures up more than 10 percentage points year over year • $1.3M of incremental EBITDA expected this year from SurfOS-driven improvements across crew, fleet, fuel, spare parts, and load factor optimization Surf On Demand Private Charter (the fastest-growing business): • Q4 2025 charter revenue up over 36% year over year using BrokerOS • 32% more bookings for top brokers • 57% faster quote-to-close • 40% more payments processed on the platform in Q1 2026 versus Q1 2025 As part of the $100M strategic transaction closed in November 2025, (SRFM) confirmed that $26M has been allocated specifically to fund SurfOS development and commercialization, including engineering expansion, go-to-market capabilities, and the buildout of its flagship products (BrokerOS, OperatorOS, and OwnerOS). SurfOS powered by Palantir. BrokerOS is commercially live. OperatorOS launches in the second half of 2026. See the full shareholder letter here. Consider Starting Your Own Research On (SRFM)... [ Company Website ] | [ Investor Relations ] 7 Reasons Why Surf Air Mobility Inc. (NYSE: SRFM) Just Landed at the Top of My Watchlist for —Tuesday, April 28, 2026 1. Management Just Raised Adjusted EBITDA Guidance by ~40%: In yesterday's joint shareholder letter, (SRFM) improved 2026 Adjusted EBITDA loss guidance from $50-$40M down to $30-$25M, while reaffirming revenue guidance of $128-$138M. 2. Insiders Are Putting Their Own Capital Back In: $15M in common equity was announced yesterday, led by the co-founders with officers, directors, and existing institutional partners adding shares alongside them. On top of that, $15M in non-dilutive, aircraft-backed credit. That is a $30M capital raise structured to minimize dilution and signal conviction. 3. SurfOS Is Live and Producing Real Numbers: BrokerOS commercially launched in December 2025 with 29 brokers enrolled and hundreds of applicants in the queue. Early internal adoption delivered a 98% Q4 airline completion rate, 10+ point on-time improvement, Q4 charter revenue up 36% YoY, and 57% faster quote-to-close. This is no longer a roadmap. It is a working product. 4. Analyst Coverage Suggests Material Upside: HC Wainwright has initiated coverage with a bullish rating. Separately, Stonegate Capital Partners has maintained coverage with a $7.05 mid-point target. Both coverage initiations underscore institutional attention on a small-cap story most investors have not caught up to yet. 5. The Palantir Moat Is Structural: (SRFM) holds an exclusive five-year agreement with Palantir Technologies for the configuration and sale of Foundry and AIP-powered software to the Part 135 regional aviation market. Palantir is one of the largest non-insider shareholders. And Shawn Pelsinger, the former Global Head of Corporate Development and Senior Counsel at Palantir who helped architect Skywise with Airbus, sits on the board. 6. BETA Partnership Eliminates Up to $100M in Previously Planned Capex: The March 2026 BETA Technologies partnership locked in a firm order for 25 electric aircraft with options for up to 75 more, and per yesterday's shareholder letter, allowed Surf Air to eliminate up to $100M in planned Cessna Caravan electrification spending, significantly limiting potential dilution while still pursuing electrification. 7. A Massive Market Tailwind Is Forming: The regional air mobility market is anticipated to expand to $75-$115B globally by 2035. The global eVTOL aircraft market is forecast to grow from $5B in 2026 to roughly $216B by 2035, an increase of more than 4,000%. Surf Air Mobility is aligning with both trajectories. Consider Starting Your Own Research On (SRFM)... [ Company Website ] | [ SRFM’s Corporate Portal ] Before you call it a night, I think it is worth taking one more look at why (SRFM) has stayed front and center. This week's shareholder letter tied everything together. 2026 guidance improved 40% on Adjusted EBITDA, and revenue guidance reaffirmed at 20-30% growth. $30M in capital raised with insiders leading the equity round. SurfOS commercially live with 29 brokers on the platform. $1.3M of incremental EBITDA expected this year from airline optimization alone. And up to $100M in planned capex eliminated. Add in the exclusive Palantir partnership powering SurfOS, a former Palantir executive on the board, and analyst coverage from HC Wainwright (Bullish) and Stonegate ($7.05 mid-point target), and it becomes clear why this company remains in focus. Zooming out, the Advanced Air Mobility backdrop is expanding quickly. Forecasts project the regional air mobility market at $75-$115B by 2035 and the eVTOL market at roughly $216B by 2035. We have all eyes on (SRFM) this morning—Tuesday, April 28, 2026. Also, keep a lookout for my next update, it could be on its way to you very shortly. And as always, please remember to do your own research. Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/27/2026 and ending on 04/28/2026 to publicly disseminate information about (SRFM:US) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid thirty eight thousand USD (“Funds”). These Funds were part of the fifteen thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (SRFM:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/srfm-8U5pn/#details

Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by alex@kryptonstreet.com

(NYSE American: MAIA) Keeps Marching Green Wednesday AM (Chart Support Strengthening?)

MAIA Biotechnology, Inc. (NYSE American: MAIA) continues to make green moves

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: MAIA) Keeps Marching Green Wednesday AM (Chart Support Strengthening?) *Click Here To Get Our Alerts Faster Via SMS* April 29th Greetings Readers, MAIA Biotechnology, Inc. (NYSE American: MAIA) continues to make green moves early Wednesday. At the time of writing this update, MAIA was holding above 4 key technical chart levels in its: 5-Day Simple Moving Average (SMA) 20-Day SMA 5-Day Exponential Moving Average (EMA) 13-Day EMA What does this mean? It means if resistance is breaking down and support is replacing it at those critical levels, it could act as the building blocks to help continue this recent vertical chart momentum. Today's green moves come just 2 weeks since a major company announcement: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer From the article: “We are thrilled to activate the expansion of our Phase 2 THIO-101 trial in the U.S., bringing our novel treatment to our country’s broad underserved NSCLC patient population. Every year, we estimate approximately 50,000 patients resistant to chemo and CPIs alone advance to third-line NSCLC in the U.S. The medical need is extensive,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. And don't forget to factor in that two separate analyst targets (more details below) are pointing to potential triple-digit upside. Review our initial (NYSE American: MAIA) report below and consider this profile for your radar. ----- As immuno-oncology continues its rapid growth, an under-the-radar player is stepping forward with an approach that may reshape how cancer is treated. The immune checkpoint inhibitor market is on a steep climb, rising from $50.29Bn in 2025 to $58.43Bn in 2026, with projections reaching $123.57Bn by 2031. Positioned within this accelerating space, this company is advancing a therapeutic strategy designed to capitalize on that momentum. Rather than simply following industry trends, its work suggests a shift in how the immune system can be leveraged against some of the most challenging cancers. And back in 2024, when I brought this profile to your attention, it exploded approx. 275% within months. With multiple analyst targets pointing to triple-digit potential upside, a massive market ripe for disruption, and several clinical updates pointing to momentum growing, this NYSE American profile is topping our watchlist again: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 1,000% Potential Upside From MAIA's Current Chart Levels. #2. Another Analyst Target Suggests Over 700% Potential Upside From Tuesday's Close. #3. A Phase 2 Expansion Trial Into The U.S. Signals A Key Company Milestone. #4. A Recent $33Mn Capital Raise Aims To Completely Fund An Ongoing Pivotal Phase 3 Trial. #5. The Company Reports Overall Survival Beyond 2 Years For 8 Patients In Ongoing Phase 2 Clinical Trial. But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 1,000% Potential Upside From MAIA's Current Chart Levels. This month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Tuesday's closing valuation, that provides MAIA with upside potential over 1,000%! Check out some key report highlights: Conclusion. Patients in the trial had advanced disease with relapsed NSCLC. We see these data as additional evidence of a sustainable response from combination treatment with ateganosine and cemiplimab. These data are consistent with prior findings showing improvements in overall survival, progression-free survival, and median survival in patients with ICI-resistant and chemo-resistant NSCLC. We are reiterating our Outperform rating and $14 price target. ----- #2. MAIA Potential Catalyst - Another Analyst Target Suggests Over 700% Potential Upside From Tuesday's Close. Last month, an analyst at Diamond Equity Research provided an update note on their (NYSE American: MAIA) coverage. In the update, they retagged MAIA with a target of $10.27. From Tuesday's close, that target provides MAIA with a potential upside of over 700%. Here's some highlights from the report: Valuation - Building on the strengthened balance sheet and improved funding visibility, we have revisited our underlying assumptions for THIO in NSCLC. We increase our probability of success (PoS) from 25% to 35%, reflecting the program’s advancement into a pivotal Phase 3 trial, supportive efficacy signals observed in earlier studies, and regulatory momentum, including Fast Track designation. In our view, the transition into a registrational study represents the achievement of a key clinical milestone and enhances visibility into the development pathway. ... Based on these revised assumptions, alongside our updated comparable company analysis, we derive an illustrative valuation of $10.27 per share, contingent on successful execution by the company. ----- #3. MAIA Potential Catalyst - A Phase 2 Expansion Trial Into The U.S. Signals A Key Company Milestone. MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diagnoses in the U.S. annually CHICAGO, April 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S. clinical site in its Phase 2 THIO-101 expansion trial of its lead investigational therapy as a third-line (3L) treatment for non-small cell lung cancer (NSCLC). “We are thrilled to activate the expansion of our Phase 2 THIO-101 trial in the U.S., bringing our novel treatment to our country’s broad underserved NSCLC patient population. Every year, we estimate approximately 50,000 patients resistant to chemo and CPIs alone advance to third-line NSCLC in the U.S. The medical need is extensive,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. The trial’s expansion into the U.S. marks a key milestone for MAIA, which is expected to open a significantly larger patient pool for evaluation of ateganosine, a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In addition to the first location, Summit Medical Group in New Jersey, MAIA intends to open four additional sites in U.S. in 2026. The trial is ongoing in Europe and Asia with 44 active sites in 6 countries. ... Read the full article here. ----- #4. MAIA Potential Catalyst - A Recent $33Mn Capital Raise Aims To Completely Fund An Ongoing Pivotal Phase 3 Trial. MAIA Biotechnology Expects Recent $33Mn Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy Strong participation in recent $33Mn common st-ock offering highlights ... confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability of technical success in Phase 3 full approval trial FDA granted Fast Track designation for dual mechanism therapy as a treatment for non-small cell lung cancer (NSCLC) CHICAGO, April 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that net proceeds from its $33Mn public offering of common st-ock in March 2026 are expected to fully fund the Company’s ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer (NSCLC). Ateganosine is a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug in third line (3L) NSCLC treatment. “We are grateful for the support and confidence shown by the heal-th-care-dedicated in-vest-ors and existing shareholders who participated in our recent offering. The $33Mn raise is expected to complete the necessary funding for our pivotal Phase 3 trial through completion,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA “Statistical assessments point to a high probability of technical success in the third-line setting if Phase 3 data is consistent with our Phase 2 trial results,” Dr. Vitoc continued. “Interim data from the Phase 3 trial, expected next year, may support a discussion with the FDA to present our case for early full commercial approval in third-line NSCLC.” ... Read the full article here. ----- #5. MAIA Potential Catalyst - The Company Reports Overall Survival Beyond 2 Years For 8 Patients In Ongoing Phase 2 Clinical Trial. MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer Potential breakthrough therapeutic targets $50Bn+ global immunotherapy market CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark. MAIA reports overall survival (OS) beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of its ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC). The patients did not receive subsequent lines of therapy. The eight patients featured in the poster include: 1 patient in third-line (3L) therapy with survival of 33 months. Expected survival in this heavily pre-treated population is 5.8 months. 4 patients in 2L therapy with survival over 30 months. Documented OS for standard of care treatment (chemotherapy or checkpoint inhibitors alone) in second-line (2L) therapy is 10.5 months. All patients have failed previous treatment (prior to THIO-101) with a checkpoint inhibitor (CPI) alone. All patients completed 29-34 cycles of therapy, except for 1 patient who completed 2 cycles of therapy with survival follow-up of 725 off therapy. 5 of the 8 patients have survival follow-up ongoing. “It’s very encouraging to see such outstanding survival from these patients extending beyond our 24-month trial protocol and without any subsequent treatment. OS surpassing two-years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO-101 Part C,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “These results illuminate ateganosine’s valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment—ateganosine sequenced by a CPI—as a potential breakthrough therapeutic option for NSCLC.” ... Read the full article here. ----- MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 1,000% Potential Upside From MAIA's Current Chart Levels. #2. Another Analyst Target Suggests Over 700% Potential Upside From Tuesday's Close. #3. A Phase 2 Expansion Trial Into The U.S. Signals A Key Company Milestone. #4. A Recent $33Mn Capital Raise Aims To Completely Fund An Ongoing Pivotal Phase 3 Trial. #5. The Company Reports Overall Survival Beyond 2 Years For 8 Patients In Ongoing Phase 2 Clinical Trial. ----- We're announcing coverage is officially underway on MAIA Biotechnology, Inc. (NYSE American: MAIA). As soon as updates are available, we'll shoot them out to you quickly. Talk soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/29/2026 and ending on 04/29/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid two hundred eleven thousand two hundred fifty USD ("Funds"). These Funds were part of the ninety two thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/maia-obgqw/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice